ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion.

ENJAYMO is a chemotherapy-free treatment proven to help stop the destruction of red blood cells (hemolysis) in cold agglutinin disease (CAD).

ENJAYMO is a chemotherapy-free treatment option that helps stop hemolysis in its tracks What Happens in people living with CAD When you have Cold Agglutinin Disease (CAD), your …

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENJAYMO safely and effectively. See full prescribing information …

ENJAYMO ® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD). It is not known if ENJAYMO is safe and effective …

ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, …

The ENJAYMO dosing schedule is designed to provide a continuous level of medicine. ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks …

information, with ENJAYMO the is medically information necessary. on this form and any prescription to Recordati Rare Diseases, Inc. (together with its parents and afiliates, …

ENJAYMO Patient Solutions is here to help you with disease and treatment education as well as financial assistance for eligible patients.

ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, …